

Global Chronic Obstructive Pulmonary Disease Treatment Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031

<https://marketpublishers.com/r/G85F4007CA13EN.html>

Date: September 2025

Pages: 113

Price: US\$ 3,132.00 (Single User License)

ID: G85F4007CA13EN

Abstracts

According to our (Global Info Research) latest study, the global Chronic Obstructive Pulmonary Disease Treatment Drug market size was valued at US\$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Chronic Obstructive Pulmonary Disease Treatment Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand

trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Chronic Obstructive Pulmonary Disease Treatment Drug market size and forecasts, in consumption value (\$ Million), 2020-2031

Global Chronic Obstructive Pulmonary Disease Treatment Drug market size and forecasts by region and country, in consumption value (\$ Million), 2020-2031

Global Chronic Obstructive Pulmonary Disease Treatment Drug market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2020-2031

Global Chronic Obstructive Pulmonary Disease Treatment Drug market shares of main players, in revenue (\$ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Chronic Obstructive Pulmonary Disease Treatment Drug

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Chronic Obstructive Pulmonary Disease Treatment Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Novartis, Merck, Abbott, Boehringer Ingelheim, AstraZeneca, Roche, Teva, Vectura, Pfizer, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Chronic Obstructive Pulmonary Disease Treatment Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Bronchodilators

PDE-4 Inhibitors

Steroids

Others

Market segment by Application

Hospital

Clinic

Others

Market segment by players, this report covers

GSK

Novartis

Merck

Abbott

Boehringer Ingelheim

AstraZeneca

Roche

Teva

Vectura

Pfizer

Mylan

Allergan

Cipla

Akorn

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Chronic Obstructive Pulmonary Disease Treatment Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Chronic Obstructive Pulmonary Disease Treatment Drug, with revenue, gross margin, and global market share of Chronic Obstructive Pulmonary Disease Treatment Drug from 2020 to 2025.

Chapter 3, the Chronic Obstructive Pulmonary Disease Treatment Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025. and Chronic Obstructive Pulmonary Disease Treatment Drug market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Chronic Obstructive Pulmonary Disease Treatment Drug.

Chapter 13, to describe Chronic Obstructive Pulmonary Disease Treatment Drug research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Chronic Obstructive Pulmonary Disease Treatment Drug by Type

1.3.1 Overview: Global Chronic Obstructive Pulmonary Disease Treatment Drug
Market Size by Type: 2020 Versus 2024 Versus 2031

1.3.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption
Value Market Share by Type in 2024

1.3.3 Bronchodilators

1.3.4 PDE-4 Inhibitors

1.3.5 Steroids

1.3.6 Others

1.4 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market by
Application

1.4.1 Overview: Global Chronic Obstructive Pulmonary Disease Treatment Drug
Market Size by Application: 2020 Versus 2024 Versus 2031

1.4.2 Hospital

1.4.3 Clinic

1.4.4 Others

1.5 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size &
Forecast

1.6 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and
Forecast by Region

1.6.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by
Region: 2020 VS 2024 VS 2031

1.6.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by
Region, (2020-2031)

1.6.3 North America Chronic Obstructive Pulmonary Disease Treatment Drug Market
Size and Prospect (2020-2031)

1.6.4 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Market Size
and Prospect (2020-2031)

1.6.5 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Market
Size and Prospect (2020-2031)

1.6.6 South America Chronic Obstructive Pulmonary Disease Treatment Drug Market
Size and Prospect (2020-2031)

1.6.7 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug

Market Size and Prospect (2020-2031)

2 COMPANY PROFILES

2.1 GSK

2.1.1 GSK Details

2.1.2 GSK Major Business

2.1.3 GSK Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.1.4 GSK Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.1.5 GSK Recent Developments and Future Plans

2.2 Novartis

2.2.1 Novartis Details

2.2.2 Novartis Major Business

2.2.3 Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.2.4 Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.2.5 Novartis Recent Developments and Future Plans

2.3 Merck

2.3.1 Merck Details

2.3.2 Merck Major Business

2.3.3 Merck Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.3.4 Merck Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.3.5 Merck Recent Developments and Future Plans

2.4 Abbott

2.4.1 Abbott Details

2.4.2 Abbott Major Business

2.4.3 Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.4.4 Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.4.5 Abbott Recent Developments and Future Plans

2.5 Boehringer Ingelheim

2.5.1 Boehringer Ingelheim Details

2.5.2 Boehringer Ingelheim Major Business

2.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.5.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.5.5 Boehringer Ingelheim Recent Developments and Future Plans

2.6 AstraZeneca

2.6.1 AstraZeneca Details

2.6.2 AstraZeneca Major Business

2.6.3 AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.6.4 AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.6.5 AstraZeneca Recent Developments and Future Plans

2.7 Roche

2.7.1 Roche Details

2.7.2 Roche Major Business

2.7.3 Roche Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.7.4 Roche Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.7.5 Roche Recent Developments and Future Plans

2.8 Teva

2.8.1 Teva Details

2.8.2 Teva Major Business

2.8.3 Teva Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.8.4 Teva Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.8.5 Teva Recent Developments and Future Plans

2.9 Vectura

2.9.1 Vectura Details

2.9.2 Vectura Major Business

2.9.3 Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.9.4 Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.9.5 Vectura Recent Developments and Future Plans

2.10 Pfizer

2.10.1 Pfizer Details

2.10.2 Pfizer Major Business

2.10.3 Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.10.4 Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.10.5 Pfizer Recent Developments and Future Plans

2.11 Mylan

2.11.1 Mylan Details

2.11.2 Mylan Major Business

2.11.3 Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.11.4 Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.11.5 Mylan Recent Developments and Future Plans

2.12 Allergan

2.12.1 Allergan Details

2.12.2 Allergan Major Business

2.12.3 Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.12.4 Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.12.5 Allergan Recent Developments and Future Plans

2.13 Cipla

2.13.1 Cipla Details

2.13.2 Cipla Major Business

2.13.3 Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.13.4 Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.13.5 Cipla Recent Developments and Future Plans

2.14 Akorn

2.14.1 Akorn Details

2.14.2 Akorn Major Business

2.14.3 Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

2.14.4 Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

2.14.5 Akorn Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue and Share by Players (2020-2025)

3.2 Market Share Analysis (2024)

3.2.1 Market Share of Chronic Obstructive Pulmonary Disease Treatment Drug by Company Revenue

3.2.2 Top 3 Chronic Obstructive Pulmonary Disease Treatment Drug Players Market Share in 2024

3.2.3 Top 6 Chronic Obstructive Pulmonary Disease Treatment Drug Players Market Share in 2024

3.3 Chronic Obstructive Pulmonary Disease Treatment Drug Market: Overall Company Footprint Analysis

3.3.1 Chronic Obstructive Pulmonary Disease Treatment Drug Market: Region Footprint

3.3.2 Chronic Obstructive Pulmonary Disease Treatment Drug Market: Company Product Type Footprint

3.3.3 Chronic Obstructive Pulmonary Disease Treatment Drug Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value and Market Share by Type (2020-2025)

4.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast by Type (2026-2031)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Application (2020-2025)

5.2 Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Forecast by Application (2026-2031)

6 NORTH AMERICA

6.1 North America Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value by Type (2020-2031)

6.2 North America Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Application (2020-2031)

6.3 North America Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Country

6.3.1 North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2020-2031)

6.3.2 United States Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

6.3.3 Canada Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

6.3.4 Mexico Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

7 EUROPE

7.1 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2031)

7.2 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2031)

7.3 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Country

7.3.1 Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2020-2031)

7.3.2 Germany Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

7.3.3 France Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

7.3.4 United Kingdom Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

7.3.5 Russia Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

7.3.6 Italy Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

8 ASIA-PACIFIC

8.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2031)

8.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2031)

8.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Region

8.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Region (2020-2031)

8.3.2 China Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

8.3.3 Japan Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

8.3.4 South Korea Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

8.3.5 India Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

8.3.6 Southeast Asia Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

8.3.7 Australia Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

9 SOUTH AMERICA

9.1 South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2031)

9.2 South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2031)

9.3 South America Chronic Obstructive Pulmonary Disease Treatment Drug Market Size by Country

9.3.1 South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2020-2031)

9.3.2 Brazil Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

9.3.3 Argentina Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and Forecast (2020-2031)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2031)

10.2 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value by Application (2020-2031)

10.3 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug
Market Size by Country

10.3.1 Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug
Consumption Value by Country (2020-2031)

10.3.2 Turkey Chronic Obstructive Pulmonary Disease Treatment Drug Market Size
and Forecast (2020-2031)

10.3.3 Saudi Arabia Chronic Obstructive Pulmonary Disease Treatment Drug Market
Size and Forecast (2020-2031)

10.3.4 UAE Chronic Obstructive Pulmonary Disease Treatment Drug Market Size and
Forecast (2020-2031)

11 MARKET DYNAMICS

11.1 Chronic Obstructive Pulmonary Disease Treatment Drug Market Drivers

11.2 Chronic Obstructive Pulmonary Disease Treatment Drug Market Restraints

11.3 Chronic Obstructive Pulmonary Disease Treatment Drug Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Chronic Obstructive Pulmonary Disease Treatment Drug Industry Chain

12.2 Chronic Obstructive Pulmonary Disease Treatment Drug Upstream Analysis

12.3 Chronic Obstructive Pulmonary Disease Treatment Drug Midstream Analysis

12.4 Chronic Obstructive Pulmonary Disease Treatment Drug Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Figures

LIST OF FIGURES

Table 1. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type, (USD Million), 2020 & 2024 & 2031

Table 2. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Table 3. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Region (2020-2025) & (USD Million)

Table 4. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Region (2026-2031) & (USD Million)

Table 5. GSK Company Information, Head Office, and Major Competitors

Table 6. GSK Major Business

Table 7. GSK Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 8. GSK Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 9. GSK Recent Developments and Future Plans

Table 10. Novartis Company Information, Head Office, and Major Competitors

Table 11. Novartis Major Business

Table 12. Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 13. Novartis Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 14. Novartis Recent Developments and Future Plans

Table 15. Merck Company Information, Head Office, and Major Competitors

Table 16. Merck Major Business

Table 17. Merck Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 18. Merck Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 19. Abbott Company Information, Head Office, and Major Competitors

Table 20. Abbott Major Business

Table 21. Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 22. Abbott Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 23. Abbott Recent Developments and Future Plans

Table 24. Boehringer Ingelheim Company Information, Head Office, and Major Competitors

Table 25. Boehringer Ingelheim Major Business

Table 26. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 27. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 28. Boehringer Ingelheim Recent Developments and Future Plans

Table 29. AstraZeneca Company Information, Head Office, and Major Competitors

Table 30. AstraZeneca Major Business

Table 31. AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 32. AstraZeneca Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 33. AstraZeneca Recent Developments and Future Plans

Table 34. Roche Company Information, Head Office, and Major Competitors

Table 35. Roche Major Business

Table 36. Roche Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 37. Roche Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 38. Roche Recent Developments and Future Plans

Table 39. Teva Company Information, Head Office, and Major Competitors

Table 40. Teva Major Business

Table 41. Teva Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 42. Teva Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 43. Teva Recent Developments and Future Plans

Table 44. Vectura Company Information, Head Office, and Major Competitors

Table 45. Vectura Major Business

Table 46. Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 47. Vectura Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 48. Vectura Recent Developments and Future Plans

Table 49. Pfizer Company Information, Head Office, and Major Competitors

Table 50. Pfizer Major Business

Table 51. Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Product and

Solutions

Table 52. Pfizer Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 53. Pfizer Recent Developments and Future Plans

Table 54. Mylan Company Information, Head Office, and Major Competitors

Table 55. Mylan Major Business

Table 56. Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 57. Mylan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 58. Mylan Recent Developments and Future Plans

Table 59. Allergan Company Information, Head Office, and Major Competitors

Table 60. Allergan Major Business

Table 61. Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 62. Allergan Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 63. Allergan Recent Developments and Future Plans

Table 64. Cipla Company Information, Head Office, and Major Competitors

Table 65. Cipla Major Business

Table 66. Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 67. Cipla Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 68. Cipla Recent Developments and Future Plans

Table 69. Akorn Company Information, Head Office, and Major Competitors

Table 70. Akorn Major Business

Table 71. Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Product and Solutions

Table 72. Akorn Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 73. Akorn Recent Developments and Future Plans

Table 74. Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue (USD Million) by Players (2020-2025)

Table 75. Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue Share by Players (2020-2025)

Table 76. Breakdown of Chronic Obstructive Pulmonary Disease Treatment Drug by Company Type (Tier 1, Tier 2, and Tier 3)

Table 77. Market Position of Players in Chronic Obstructive Pulmonary Disease

Treatment Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024

Table 78. Head Office of Key Chronic Obstructive Pulmonary Disease Treatment Drug Players

Table 79. Chronic Obstructive Pulmonary Disease Treatment Drug Market: Company Product Type Footprint

Table 80. Chronic Obstructive Pulmonary Disease Treatment Drug Market: Company Product Application Footprint

Table 81. Chronic Obstructive Pulmonary Disease Treatment Drug New Market Entrants and Barriers to Market Entry

Table 82. Chronic Obstructive Pulmonary Disease Treatment Drug Mergers, Acquisition, Agreements, and Collaborations

Table 83. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (USD Million) by Type (2020-2025)

Table 84. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Share by Type (2020-2025)

Table 85. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Forecast by Type (2026-2031)

Table 86. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2025)

Table 87. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Forecast by Application (2026-2031)

Table 88. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2025) & (USD Million)

Table 89. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2026-2031) & (USD Million)

Table 90. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2025) & (USD Million)

Table 91. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2026-2031) & (USD Million)

Table 92. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 93. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 94. Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2025) & (USD Million)

Table 95. Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2026-2031) & (USD Million)

Table 96. Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2025) & (USD Million)

Table 97. Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2026-2031) & (USD Million)

Table 98. Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 99. Europe Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 100. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2025) & (USD Million)

Table 101. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2026-2031) & (USD Million)

Table 102. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2025) & (USD Million)

Table 103. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2026-2031) & (USD Million)

Table 104. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Region (2020-2025) & (USD Million)

Table 105. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Region (2026-2031) & (USD Million)

Table 106. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2025) & (USD Million)

Table 107. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2026-2031) & (USD Million)

Table 108. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2025) & (USD Million)

Table 109. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2026-2031) & (USD Million)

Table 110. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 111. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 112. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2020-2025) & (USD Million)

Table 113. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type (2026-2031) & (USD Million)

Table 114. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2020-2025) & (USD Million)

Table 115. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application (2026-2031) & (USD Million)

Table 116. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment

Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 117. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment

Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 118. Global Key Players of Chronic Obstructive Pulmonary Disease Treatment

Drug Upstream (Raw Materials)

Table 119. Global Chronic Obstructive Pulmonary Disease Treatment Drug Typical Customers

LIST OF FIGURES

Figure 1. Chronic Obstructive Pulmonary Disease Treatment Drug Picture

Figure 2. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Type, (USD Million), 2020 & 2024 & 2031

Figure 3. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Type in 2024

Figure 4. Bronchodilators

Figure 5. PDE-4 Inhibitors

Figure 6. Steroids

Figure 7. Others

Figure 8. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Figure 9. Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Application in 2024

Figure 10. Hospital Picture

Figure 11. Clinic Picture

Figure 12. Others Picture

Figure 13. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value, (USD Million): 2020 & 2024 & 2031

Figure 14. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value and Forecast (2020-2031) & (USD Million)

Figure 15. Global Market Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)

Figure 16. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Region (2020-2031)

Figure 17. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Region in 2024

Figure 18. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 19. Europe Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value (2020-2031) & (USD Million)

Figure 20. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 21. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 22. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 23. Company Three Recent Developments and Future Plans

Figure 24. Global Chronic Obstructive Pulmonary Disease Treatment Drug Revenue Share by Players in 2024

Figure 25. Chronic Obstructive Pulmonary Disease Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024

Figure 26. Market Share of Chronic Obstructive Pulmonary Disease Treatment Drug by Player Revenue in 2024

Figure 27. Top 3 Chronic Obstructive Pulmonary Disease Treatment Drug Players Market Share in 2024

Figure 28. Top 6 Chronic Obstructive Pulmonary Disease Treatment Drug Players Market Share in 2024

Figure 29. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Share by Type (2020-2025)

Figure 30. Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Share Forecast by Type (2026-2031)

Figure 31. Global Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Share by Application (2020-2025)

Figure 32. Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Share Forecast by Application (2026-2031)

Figure 33. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Type (2020-2031)

Figure 34. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Application (2020-2031)

Figure 35. North America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Country (2020-2031)

Figure 36. United States Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 37. Canada Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 38. Mexico Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 39. Europe Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value Market Share by Type (2020-2031)

Figure 40. Europe Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value Market Share by Application (2020-2031)

Figure 41. Europe Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value Market Share by Country (2020-2031)

Figure 42. Germany Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value (2020-2031) & (USD Million)

Figure 43. France Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value (2020-2031) & (USD Million)

Figure 44. United Kingdom Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value (2020-2031) & (USD Million)

Figure 45. Russia Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value (2020-2031) & (USD Million)

Figure 46. Italy Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 47. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value Market Share by Type (2020-2031)

Figure 48. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value Market Share by Application (2020-2031)

Figure 49. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Drug

Consumption Value Market Share by Region (2020-2031)

Figure 50. China Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 51. Japan Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 52. South Korea Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 53. India Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 54. Southeast Asia Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 55. Australia Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 56. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Type (2020-2031)

Figure 57. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Application (2020-2031)

Figure 58. South America Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Country (2020-2031)

Figure 59. Brazil Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 60. Argentina Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 61. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Type (2020-2031)

Figure 62. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Application (2020-2031)

Figure 63. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value Market Share by Country (2020-2031)

Figure 64. Turkey Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 65. Saudi Arabia Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 66. UAE Chronic Obstructive Pulmonary Disease Treatment Drug Consumption Value (2020-2031) & (USD Million)

Figure 67. Chronic Obstructive Pulmonary Disease Treatment Drug Market Drivers

Figure 68. Chronic Obstructive Pulmonary Disease Treatment Drug Market Restraints

Figure 69. Chronic Obstructive Pulmonary Disease Treatment Drug Market Trends

Figure 70. Porters Five Forces Analysis

Figure 71. Chronic Obstructive Pulmonary Disease Treatment Drug Industrial Chain

Figure 72. Methodology

Figure 73. Research Process and Data Source

I would like to order

Product name: Global Chronic Obstructive Pulmonary Disease Treatment Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Product link: <https://marketpublishers.com/r/G85F4007CA13EN.html>

Price: US\$ 3,132.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G85F4007CA13EN.html>